GOLDEN THROAT (06896) will distribute a final dividend of 0.5 Hong Kong dollars per share on June 26.
GOLDEN THROAT (06896) announced that the company will distribute a final dividend of 0.5 per share on June 26, 2025...
GOLDEN THROAT: ANNUAL REPORT 2024
GOLDEN THROAT (06896) announced its annual performance, with a profit attributable to shareholders of 0.319 billion yuan, an increase of 27.37% year-on-year.
GOLDEN THROAT (06896) announced its annual performance for the year ending December 31, 2024, with the group achieving a revenue of 11....
Express News | Golden Throat Holdings Group FY Gross Margin 75.5%
Express News | Golden Throat Holdings Group FY Net Income RMB 318.6 Million
Express News | Golden Throat Holdings Group FY Revenue RMB 1,185 Million
GOLDEN THROAT: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024ANDFURTHER CHANGE IN USE OF PROCEEDS
Golden Throat Holdings Group Company Limited's (HKG:6896) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Golden Throat Holdings Expects Significant Profit Growth in 2024
GOLDEN THROAT (06896.HK) expects annual revenue and profit to increase by approximately 20% to 25%.
Gelonghui, March 18: GOLDEN THROAT (06896.HK) announced that for the year ending December 31, 2024, the group expects revenue and profit to increase by approximately 20% to 25% compared to the same period in 2023. The main reason for the increase in revenue and profit is the significant enhancement in the group's sales throughout 2024.
Express News | Golden Throat Holdings - Expects 20%-25% Increase in Operating Revenue and Profit in Year Respectively
GOLDEN THROAT: POSITIVE PROFIT ALERT
Golden Throat Holdings Group to Review Annual Results and Dividend Declaration
GOLDEN THROAT (06896.HK) will hold a Board of Directors meeting on March 28 to approve the annual results.
Gelonghui, March 18 - GOLDEN THROAT (06896.HK) announced that the company will hold a Board of Directors meeting on March 28, 2025, to approve the announcement of the annual performance for the year ending December 31, 2024, and to consider the proposal for the distribution of a final dividend (if any).
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
GOLDEN THROAT: 2024 Interim Report
Golden Throat Reports Robust Mid-Year Growth
Golden Throat (06896) announced its interim performance with a net profit of approximately 0.134 billion yuan, an increase of approximately 9.9% compared to the same period last year.
Golden Throat (06896) announced its mid-term performance for 2024, with a profit of approximately 0.5245 billion yuan, a year-on-year increase of about 9.4...
Express News | Golden Throat Holdings Group H1 Net Income RMB 134.2 Million
Express News | Golden Throat Holdings Group H1 Gross Profit RMB 391.8 Million